UY36315A - COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. - Google Patents

COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.

Info

Publication number
UY36315A
UY36315A UY0001036315A UY36315A UY36315A UY 36315 A UY36315 A UY 36315A UY 0001036315 A UY0001036315 A UY 0001036315A UY 36315 A UY36315 A UY 36315A UY 36315 A UY36315 A UY 36315A
Authority
UY
Uruguay
Prior art keywords
avß6
antigonist
integrine
compounds
new
Prior art date
Application number
UY0001036315A
Other languages
English (en)
Inventor
Ashley Paul Hancock
John Martin Pritchard
Joanna Mary Redmond
Matthew Howard James Campbell-Crawford
Niall Andrew Anderson
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of UY36315A publication Critical patent/UY36315A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de fórmula I, en la que R representa H o F, o una sal del mismo.
UY0001036315A 2014-09-26 2015-09-22 COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6. UY36315A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417011.2A GB201417011D0 (en) 2014-09-26 2014-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
UY36315A true UY36315A (es) 2016-04-29

Family

ID=51901167

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036315A UY36315A (es) 2014-09-26 2015-09-22 COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.

Country Status (15)

Country Link
US (1) US10000489B2 (es)
EP (1) EP3197893B1 (es)
JP (1) JP6665169B2 (es)
KR (1) KR20170063590A (es)
CN (1) CN107074849A (es)
AR (1) AR101995A1 (es)
AU (1) AU2015320859A1 (es)
BR (1) BR112017006253A2 (es)
CA (1) CA2962326A1 (es)
ES (1) ES2704525T3 (es)
GB (1) GB201417011D0 (es)
RU (1) RU2017114346A (es)
TW (1) TW201629057A (es)
UY (1) UY36315A (es)
WO (1) WO2016046226A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
KR102510858B1 (ko) 2016-11-08 2023-03-15 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 아졸 아미드 및 아민
JP7264810B2 (ja) 2016-11-08 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのシクロブタン－およびアゼチジン－含有の単環およびスピロ環式化合物
JP7097358B2 (ja) 2016-11-08 2022-07-07 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としての３－置換プロピオン酸
MX2019005233A (es) 2016-11-08 2019-08-12 Squibb Bristol Myers Co Pirrolamidas como inhibidores de la integrina alfa v.
MA46745A (fr) 2016-11-08 2021-03-31 Bristol Myers Squibb Co Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
CA3054792A1 (en) 2017-02-28 2018-09-07 Morphic Therapeutic, Inc. Inhibitors of .alpha.v.beta.6 integrin
CN116283977A (zh) 2017-02-28 2023-06-23 莫菲克医疗股份有限公司 αvβ6整合蛋白的抑制剂
CN107823208A (zh) * 2017-10-25 2018-03-23 南京多宝生物科技有限公司 吗啉类化合物在制备治疗和预防肾纤维化药物中的应用
CN111433207B (zh) 2017-11-07 2023-07-25 百时美施贵宝公司 作为αV整合素抑制剂的吡咯并吡嗪衍生物
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
CN112805001B (zh) 2018-08-29 2024-07-23 莫菲克医疗股份有限公司 抑制αvβ6整联蛋白
WO2020081154A1 (en) 2018-08-29 2020-04-23 Morphic Therapeutic, Inc. INHIBITORS OF ανβ6 INTEGRIN
TW202028179A (zh) * 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用
US11034710B2 (en) * 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2023225119A1 (en) * 2022-05-18 2023-11-23 Pliant Therapeutics, Inc. Stabilization of integrin inhibitors
WO2024129931A1 (en) 2022-12-14 2024-06-20 Alnylam Pharmaceuticals, Inc. ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136495A0 (en) 1997-12-17 2001-06-14 Merck & Co Inc Integrin receptor antagonists
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
CN1589145A (zh) 1999-06-02 2005-03-02 麦克公司 αv整联蛋白受体拮抗剂
CA2376077A1 (en) 1999-06-23 2000-12-28 Merck & Co., Inc. Integrin receptor antagonists
CA2386030A1 (en) * 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
IL149313A0 (en) 1999-11-08 2002-11-10 Merck & Co Inc Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
WO2001096334A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
JP2004504349A (ja) 2000-07-26 2004-02-12 メルク　エンド　カムパニー　インコーポレーテッド αｖインテグリン受容体拮抗薬
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
CA2432504A1 (en) 2001-01-03 2002-07-11 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
JP2006518333A (ja) 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
RS53151B (en) 2007-03-23 2014-06-30 Amgen Inc. 3-SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR (PI3K)
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CN107531699A (zh) 2015-02-19 2018-01-02 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
EP3268369A4 (en) 2015-03-10 2018-08-08 The Regents of The University of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
AR101995A1 (es) 2017-01-25
ES2704525T3 (es) 2019-03-18
CN107074849A (zh) 2017-08-18
EP3197893B1 (en) 2018-10-24
RU2017114346A (ru) 2018-11-02
US10000489B2 (en) 2018-06-19
CA2962326A1 (en) 2016-03-31
BR112017006253A2 (pt) 2017-12-12
JP6665169B2 (ja) 2020-03-13
US20170298063A1 (en) 2017-10-19
EP3197893A1 (en) 2017-08-02
TW201629057A (zh) 2016-08-16
AU2015320859A1 (en) 2017-03-09
GB201417011D0 (en) 2014-11-12
KR20170063590A (ko) 2017-06-08
WO2016046226A1 (en) 2016-03-31
JP2017528503A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
EA201891211A1 (ru) Ингибиторы cxcr2
UY36314A (es) NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA avß6.
TR201905829T4 (tr) Buzdolabı.
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
DOP2017000178A (es) Inhibidores selectivos de bace1
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
TR201909606T4 (tr) Pi̇razollari hazirlamak i̇çi̇n i̇şlem
DK3135668T3 (da) Ny disubstitueret 1,2,4-triazin-forbindelse
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
BR112017005883A2 (pt) compostos herbicidas
AR105967A1 (es) Sales de un inhibidor de pim quinasa
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
BR112016029117A2 (pt) compostos herbicidas
BR112017023150A2 (pt) compostos herbicidas.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
BR112016027455A2 (pt) moduladores ppar
DK3374357T3 (da) Disubstituerede diaryloxybenzoheterodiazol-forbindelser
BR112017002139A2 (pt) ?método para preparar um composto?
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
CL2016003154A1 (es) Composiciones herbicidas sólidas que contienen un fitoprotector

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705